CENTOGENE offers genetic testing to establish a molecular diagnosis and differentiate TSC from phenotypically overlapping conditions.
Public source
Publisher name
Public post
🚨 When seizures occur alongside characteristic skin changes, kidney abnormalities, or developmental and behavioral concerns, tuberous sclerosis complex (TSC) may be an…
Company
CENTOGENE
Empowering precision medicine through advanced diagnosis
- Industry
- Biotechnology Research
- Location
- Rostock, DE
- Company size
- 201–500 employees
About CENTOGENE
CENTOGENE is a leading company in the field of genetic diagnostics and precision medicine, dedicated to transforming clinical, genetic, and biochemical data into medical solutions for patients. Based in Rostock, Germany, the company operates globally. Founded in 2006 with the mission of revolutionizing the diagnosis of rare diseases, CENTOGENE has since scaled its capabilities to diagnose more than 2,500 rare diseases in over 100 countries, building one of the largest genetic databases in the world (1,000,000 individuals) while developing cutting-edge technology for the interpretation of genetic data. With over 350 scientific publications, CENTOGENE is a key partner for physicians in rapid and accurate genetic diagnosis, and for pharmaceutical companies focused on developing treatments for orphan diseases.
See moreLatest activity
Latest activity from CENTOGENE
3 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
GeneDx
GeneDx published a study in the journal Genetics in Medicine highlighting the benefits of rapid genome sequencing implemented across pediatric hospital care.
Research & Knowledge
Ambry Genetics
Ambry Genetics
Products & Services
Baylor Genetics
Baylor Genetics offers Rapid Whole Genome Sequencing (rWGS) as a first-tier test for infants and children in the NICU/PICU to accelerate diagnosis and shorten hospital stays.
Research & Knowledge
Variantyx
Variantyx published a case study involving a 14-month-old patient presenting with profound global developmental delay and multiple congenital anomalies, including complex craniofacial features, cardiac defects, and skeletal abnormalities, who was tested with Variantyx Genomic Unity® and had negative results after a year of rapid whole genome trio testing in the NICU.
Research & Knowledge
Sano Genetics